在全丹麦结直肠癌队列中评估循环肿瘤DNA检测的潜在临床效用
研究纳入851例接受根治性治疗的II-III期结直肠癌患者,基于肿瘤组织全外显子测序选择突变靶点,用单靶点数字PCR检测术后及系列血浆ctDNA。术后和系列ctDNA检测均对复发有预后价值(HR分别为11.3和30.7,P均<0.001),复发患者至样本采集结束时累积ctDNA检出率为87%。
要点
- 术后ctDNA检测与复发强相关(HR=11.3,95%CI 7.8-16.4,P<0.001)。
- 系列ctDNA检测与复发强相关(HR=30.7,95%CI 20.2-46.7,P<0.001)。
- 复发患者中肺转移(4/21检出)和腹膜转移(2/10检出)术后ctDNA检测较困难。
核心结论
- 基于851例II-III期结直肠癌患者的结果显示,个性化dPCR方法可有效检测术后微小残留病灶,并有望用于复发监测的系列ctDNA检测。
研究设计与样本
- 研究纳入851例接受根治性治疗的II-III期结直肠癌患者,基于匹配肿瘤与胚系DNA的全外显子测序选择突变靶点进行数字PCR分析。
- 术后60天内采集8 ml血浆样本,其中246例患者子集每3-4个月采集一次,最长随访36个月。
- 采用单靶点数字PCR检测ctDNA。
主要发现
- 术后ctDNA检测对复发有预后价值(HR=11.3,95%CI 7.8-16.4,P<0.001)。
- 系列ctDNA检测对复发有预后价值(HR=30.7,95%CI 20.2-46.7,P<0.001)。
- 复发患者至样本采集结束时累积ctDNA检出率为87%。
- ctDNA增长速率对生存有预后价值(HR=2.6,95%CI 1.5-4.4,P=0.001)。
- 复发患者中,术后ctDNA检测对肺转移(21例中检出4例)和腹膜转移(10例中检出2例)较困难。
关键数值与推荐
- 通过修改判定样本ctDNA阳性的cut-off值,可针对不同临床情境调整检测的敏感性和特异性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasingly, circulating tumor DNA (ctDNA) is proposed as a tool for minimal residual disease (MRD) assessment. Digital PCR (dPCR) offers low analysis costs and turnaround times of less than a day, making it ripe for clinical implementation. Here, we used tumor-informed dPCR for ctDNA detection in a large colorectal cancer (CRC) cohort to evaluate the potential for post-operative risk assessment and serial monitoring, and how the metastatic site may impact ctDNA detection. Additionally, we assessed how altering the ctDNA-calling algorithm could customize performance for different clinical settings. PATIENTS AND METHODS: Stage II-III CRC patients (N = 851) treated with a curative intent were recruited. Based on whole-exome sequencing on matched tumor and germline DNA, a mutational target was selected for dPCR analysis. Plasma samples (8 ml) were collected within 60 days after operation and-for a patient subset (n = 246)-every 3-4 months for up to 36 months. Single-target dPCR was used for ctDNA detection. RESULTS: Both post-operative and serial ctDNA detection were prognostic of recurrence [hazard ratio (HR) = 11.3, 95% confidence interval (CI) 7.8-16.4, P < 0.001; HR = 30.7, 95% CI 20.2-46.7, P < 0.001], with a cumulative ctDNA detection rate of 87% at the end of sample collection in recurrence patients. The ctDNA growth rate was prognostic of survival (HR = 2.6, 95% CI 1.5-4.4, P = 0.001). In recurrence patients, post-operative ctDNA detection was challenging for lung metastases (4/21 detected) and peritoneal metastases (2/10 detected). By modifying the cut-off for calling a sample ctDNA positive, we were able to adjust the sensitivity and specificity of our test for different clinical contexts. CONCLUSIONS: The presented results from 851 stage II-III CRC patients demonstrate that our personalized dPCR approach effectively detects MRD after operation and shows promise for serial ctDNA detection for recurrence surveillance. The ability to adjust sensitivity and specificity shows exciting potential to customize the ctDNA caller for specific clinical settings.
引用
- Henriksen TV, Demuth C, Frydendahl A, et al. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Ann Oncol. 2023. PMID: 37992872. doi:10.1016/j.annonc.2023.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。